Quest Diagnostics has completed the sale of its rights to royalties from commercialization of the drug candidate ibrutinib to Royalty Pharma for $485 million in cash, as part of pharma deals. Read the full story

The Lymphoma Partnering 2007-2012 provides understanding and access to the lymphoma partnering deals and agreements entered into by the worlds leading healthcare companies Read the full story